SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
X	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* Wittman Lori (Last) (First) (Middle) 191 N. WACKER DRIVE SUITE 1200 (Street) CHICAGO IL 60606 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol Care Capital Properties, Inc. [ CCP ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) EVP and CFO
	3. Date of Earliest Transaction (Month/Day/Year) 08/17/2017
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/17/2017		A		14,768(1)	A	(1)	93,521	D
Common Stock	08/17/2017		D		93,521(2)	D	(2)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$27.07	08/17/2017		D			1,620	(3)(6)	03/09/2022	Common Stock	1,620	(6)	0	D
Stock Option (Right to Buy)	$34.37	08/17/2017		D			8,577	(3)(6)	03/08/2023	Common Stock	8,577	(6)	0	D
Stock Option (Right to Buy)	$29.57	08/17/2017		D			25,611	(3)(6)	03/07/2024	Common Stock	25,611	(6)	0	D
Stock Option (Right to Buy)	$34.16	08/17/2017		D			28,441	(4)(6)	03/06/2025	Common Stock	28,441	(6)	0	D
Stock Option (Right to Buy)	$29.94	08/17/2017		D			57,851	(5)(6)	01/27/2026	Common Stock	57,851	(6)	0	D

Explanation of Responses:

1. Pursuant to an Agreement and Plan of Merger, dated May 7, 2017 (the "Merger Agreement"), by and among Sabra Health Care REIT, Inc., a Maryland corporation ("Sabra"), Sabra Health Care Limited Partnership, a Delaware limited partnership, PR Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of Sabra ("Merger Sub"), Care Capital Properties, Inc., a Delaware corporation (the "Issuer"), and Care Capital Properties, LP, a Delaware limited partnership, the outstanding performance-based restricted stock units held by the Reporting Person immediately prior to the effective time of the merger (the "Merger") of Issuer with and into Merger Sub vested in full and were converted into an aggregate 14,768 shares of Issuer common stock.

2. Pursuant to the Merger Agreement, each outstanding share of the Issuer's common stock was exchanged on August 17, 2017 for the right to receive 1.123 newly issued shares of Sabra's common stock (the "Merger Consideration"), subject to certain adjustments as set forth in the Merger Agreement. The closing price of shares of Sabra's common stock on August 16, 2017 was $21.72 per share.

3. Fully vested.

4. A portion of these options were scheduled to vest on March 6, 2018.

5. These options were granted on January 27, 2016 and were scheduled to vest in three equal installments beginning on the first anniversary of the date of the grant.

6. Pursuant to the Merger Agreement, each stock option, whether vested or unvested, that was outstanding and unexercised immediately prior to the effective time of the Merger vested in full (if not already vested), was assumed by Sabra and was converted into a stock option award to purchase a number of shares of Sabra common stock, at an exercise price per share of Sabra common stock under such option, based on the exchange ratio provided in the Merger Agreement, and will remain exercisable in accordance with the terms and conditions applicable to the original stock option.

	Lori B. Wittman, By: Kristen M. Benson, Attorney-in-Fact	08/18/2017
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.